Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Sirexatamab (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Aug 2023 Status changed from not yet recruiting to recruiting.
- 27 Feb 2023 Status changed from planning to not yet recruiting.
- 20 Jul 2022 New trial record